Abiomed Showcases Impella® Technology that Enables Heart Recovery at ACC with 25 Presentations
05. März 2018 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 25...
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
14. Februar 2018 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced that it has received an...
Abiomed Announces Peripartum and Postpartum Cardiomyopathy Approval and Women’s Initiative for Heart Recovery
13. Februar 2018 09:30 ET
|
ABIOMED, Inc.
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new...
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
13. Februar 2018 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received an...
アビオメッド、2018年度第3四半期の業績を発表、収入は前年度比34%増の1億5,400万ドル
01. Februar 2018 23:59 ET
|
ABIOMED, Inc.
マサチューセッツ州ダンバース及びサンフランシスコ発 , Feb. 02, 2018 (GLOBE NEWSWIRE) -- 画期的な心臓サポートテクノロジーのリーディング･プロバイダーであるアビオメッド (Abiomed, Inc.、NASDAQ:ABMD) は本日、2018年度第3四半期に1億5,400万ドル (約168億9,000万円)...
Abiomed Announces Q3 FY 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
01. Februar 2018 07:00 ET
|
ABIOMED, Inc.
U.S. Patient Utilization Grew 33%, Year Over Year DANVERS, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery...
Abiomed Third Quarter Fiscal 2018 Earnings and Conference Call Notification
12. Januar 2018 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, February 1, 2018, the Company will release financial results for the third quarter of fiscal...
アビオメッド、2018年度第３四半期の概算収益を発表、前年度比34%増の1億5,400万ドル
08. Januar 2018 18:21 ET
|
ABIOMED, Inc.
米国マサチューセッツ州ダンバースおよびサンフランシスコ発, Jan. 09, 2018 (GLOBE NEWSWIRE) -- アビオメッド、2018年度第３四半期の概算収益を発表、前年度比34%増の1億5,400万ドル 2018年1月8日、米国マサチューセッツ州ダンバースおよびサンフランシスコ発（グローブニューズワイヤ） --...
Abiomed Announces Preliminary Q3 FY 2018 Revenue of $154 Million, Up 34% Over Prior Year
08. Januar 2018 07:00 ET
|
ABIOMED, Inc.
DANVERS, Mass. and SAN FRANCISCO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary, unaudited,...
Abiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
29. Dezember 2017 08:00 ET
|
ABIOMED, Inc.
DANVERS, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman,...